Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 13;6(5):e712.
doi: 10.1097/HS9.0000000000000712. eCollection 2022 May.

Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-up

Martin Dreyling  1 , Andre Goy  2 , Georg Hess  3 , Brad S Kahl  4 , José-Ángel Hernández-Rivas  5 , Natasha Schuier  6 , Keqin Qi  7 , Sanjay Deshpande  8 , Angeline Zhu  8 , Lori Parisi  8 , Michael L Wang  9
Affiliations

Long-term Outcomes With Ibrutinib Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma: A Pooled Analysis of 3 Clinical Trials With Nearly 10 Years of Follow-up

Martin Dreyling et al. Hemasphere. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Kaplan-Meier estimate of PFS and OS with ibrutinib. (A) PFS by best response (CR versus PR); (B) PFS by prior LOT; (C) OS by prior LOT; (D) PFS with ibrutinib versus estimated PFS on prior regimen; (E) PFS with ibrutinib in patients with one prior LOT by frontline POD status (POD24 versus POD ≥24). CR = complete response; LOT = line of treatment; OS = overall survival; PFS = progression-free survival; POD = progression of disease; PR = partial response.
See this image and copyright information in PMC

References

    1. Kumar A, Sha F, Toure A, et al. Patterns of survival in patients with recurrent mantle cell lymphoma in the modern era: progressive shortening in response duration and survival after each relapse. Blood Cancer J. 2019;9:50. - PMC - PubMed
    1. Rule S, Dreyling M, Hess G, et al. Overall survival outcomes in patients with mantle-cell lymphoma treated with ibrutinib: a pooled analysis of 370 patients from 3 international open-label studies. Presented at: European Hematology Association; June 9-12, 2016; Copenhagen, Denmark. Abstract S438. Available at: https://library.ehaweb.org/eha/2016/21st/135194/simon.rule.overall.survi.... Accessed March 28, 2022.
    1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology - B-Cell Lymphomas. Version 5, September 22, 2021. Available at: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1480. Accessed November 1, 2021.
    1. Dreyling M, Campo E, Hermine O, et al. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv62–iv71. - PubMed
    1. Dreyling M, Jurczak W, Jerkeman M, et al. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet. 2016;387:770–778. - PubMed